Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approa... Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to cannabinoid-based therapies, including those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds that promote the effectiveness of the endocannabinoid system. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease. Mehr anzeigen
The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif...
SOLANA BEACH, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
SOLANA BEACH, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
SOLANA BEACH, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
SOLANA BEACH, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
SOLANA BEACH, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0458 | -3.78512396694 | 1.21 | 1.21 | 1.12 | 13366 | 1.17483503 | CS |
| 4 | 0.1342 | 13.0291262136 | 1.03 | 1.21 | 1.0101 | 26906 | 1.13078135 | CS |
| 12 | 0.0042 | 0.362068965517 | 1.16 | 1.32 | 0.91 | 35065 | 1.1324041 | CS |
| 26 | -0.1958 | -14.3970588235 | 1.36 | 1.43 | 0.91 | 20407 | 1.15897483 | CS |
| 52 | -0.2258 | -16.2446043165 | 1.39 | 1.75 | 0.91 | 34892 | 1.30077389 | CS |
| 156 | 0.7942 | 214.648648649 | 0.37 | 7.2 | 0.2599 | 226311 | 1.34468721 | CS |
| 260 | -1.1258 | -49.1615720524 | 2.29 | 7.2 | 0.2599 | 1234562 | 1.40474691 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
